← Back to Search

Device

Enhanced tDCS for Alzheimer's Disease

N/A

Waitlist Available

Research Sponsored by Baycrest

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 months

Awards & highlights

Study Summary

This trial is testing whether a more intense electrical current can help people with Alzheimer's disease more than the standard current.

Who is the study for?

This trial is for individuals with mild to moderate Alzheimer's Disease, who score between 18 and 25 on the MoCA test, indicating their cognitive abilities. They must also have a certain score on the Cambridge Naming Task. People with significant heart disease, alcohol or drug abuse history, stroke or traumatic brain injury (TBI), or those with shunts or metal in their body cannot participate.Check my eligibility

What is being tested?

The study is testing whether a stronger intensity of transcranial direct current stimulation (tDCS) at 4mA combined with naming training can improve language skills better than the conventional level of 2mA in people living with Alzheimer's Disease.See study design

What are the potential side effects?

While tDCS is generally considered safe, potential side effects may include mild tingling, itching or burning sensation on the scalp where electrodes are placed; headache; fatigue; and nausea.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Naming Training

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Placebo Group

Group I: 4mA StimulationExperimental Treatment1 Intervention

Group II: 2mA StimulationActive Control1 Intervention

Group III: SHAMPlacebo Group1 Intervention

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Alzheimer's SocietyOTHER

9 Previous Clinical Trials

9,241 Total Patients Enrolled

BaycrestLead Sponsor

43 Previous Clinical Trials

5,925 Total Patients Enrolled

Media Library

transcranial direct current stimulation (Device) Clinical Trial Eligibility Overview. Trial Name: NCT05509387 — N/A

Alzheimer's Disease Research Study Groups: 4mA Stimulation, 2mA Stimulation, SHAM

Alzheimer's Disease Clinical Trial 2023: transcranial direct current stimulation Highlights & Side Effects. Trial Name: NCT05509387 — N/A

transcranial direct current stimulation (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05509387 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment currently taking on new volunteers?

"According to clinicaltrials.gov, this research study is now closed for recruitment; it was first posted on the 1st of September 2022 and last modified on August 19th 2022. However, 552 other trials are still actively seeking participants at present."

Answered by AI

Does this research study permit elderly individuals to participate?

"This trial is open to individuals aged 50 to 90. For those younger than 18, there are 23 separate studies available and 542 for seniors over 65 years of age."

Answered by AI

To whom is this clinical trial open for enrollment?

"In this study, 42 individuals aged between 50 and 90 with Alzheimer's disease are eligible for enrolment. Additionally, they must exhibit mild or moderate symptoms of AD, score 18 to 25 on the MoCA test, and demonstrate sufficient performance on the Cambridge Naming Task during pre-assessment."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheimer's Disease

Tyler Roncero 2022. "Investigating if a Stronger tDCS Intensity is More Effective for Improving Naming Ability in People Living With Alzheimer's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05509387.